Related
European Commission Approves Amicus’ Pombiliti in Patients with Late-Onset Pompe Disease
Rare Daily Staff The European Commission has granted approval for Amicus Therapeutics’ Pombiliti, a long-term enzyme replacement […]
Read moreEMA Amends Policy of Orphan Designations of Therapies for Inherited Retinal Dystrophies
Rare Daily Staff The European Medicines Agency’s Committee on Orphan Medicinal Products said it has amended its […]
Read moreCAMP4 Raises $100 Million to Accelerate Expansion of Regulatory RNA-Targeting Platform and Advance Rare Disease Pipeline
Rare Daily Staff CAMP4 Therapeutics said it closed a $100 million series B round to advance the […]
Read moreFDA Releases Action Plan for Rare Neurodegenerative Diseases, Including ALS
Rare Daily Staff The U.S. Food and Drug Administration unveiled its Action Plan for Rare Neurodegenerative Diseases, […]
Read moreFDA’s CDER Launches Accelerating Rare Disease Cures Program
Rare Daily Staff The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research announced the […]
Read moreMarksist Thought and Capital Ideas
Though gene therapies, like small molecule drugs, need to be shown to be safe and effective in […]
Read moreFDA Releases Draft Guidance for Gene Editing Products
Rare Daily Staff The U.S. Food and Drug Administration released draft guidance for gene therapy products that […]
Read moreFDA Issues Guidances on N-of-1 ASO Therapies
Read moreFDA Issues Draft Guidance on Use of Registries to Support Regulatory Decision-Making
Rare Daily Staff The U.S. Food and Drug Administration has released a draft guidance for industry on […]
Read more